mSC-EVS has been shown to reduce mtDNA damage and inflammation after AKI in an ischemia-reperfusion–induced AKI model, which is dependent on the mitochondrial transcription factor A (TFAM) pathway. This evidence concerns the gene TFAM and acute kidney injury.